These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 11770837

  • 1. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
    Okopien B, Cwalina L, Lebek M, Kowalski J, Zielinski M, Wisniewska-Wanat M, Kalina Z, Herman ZS.
    Int J Clin Pharmacol Ther; 2001 Dec; 39(12):551-7. PubMed ID: 11770837
    [Abstract] [Full Text] [Related]

  • 2. Extralipid effects of micronized fenofibrate in dyslipidemic patients.
    Okopień B, Haberka M, Madej A, Belowski D, Labuzek K, Krysiak R, Zieliński M, Basiak M, Herman ZS.
    Pharmacol Rep; 2006 Dec; 58(5):729-35. PubMed ID: 17085865
    [Abstract] [Full Text] [Related]

  • 3. [Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia].
    Okopień B, Cwalina Ł, Haberka M, Kowalski J, Zieliński M, Szwed Z, Kalina Z, Herman ZS.
    Pol Merkur Lekarski; 2002 Dec; 13(78):465-9. PubMed ID: 12666442
    [Abstract] [Full Text] [Related]

  • 4. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M, de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C, Princen HM, Kooistra T.
    Thromb Haemost; 1997 Oct; 78(4):1167-72. PubMed ID: 9364979
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials.
    Ramjattan BR, Callaghan DJ, Theiss U.
    Clin Ther; 2002 Jul; 24(7):1105-16. PubMed ID: 12182255
    [Abstract] [Full Text] [Related]

  • 6. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
    Kockx M, Princen HM, Kooistra T.
    Thromb Haemost; 1998 Dec; 80(6):942-8. PubMed ID: 9869165
    [Abstract] [Full Text] [Related]

  • 7. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
    Insua A, Massari F, Rodríguez Moncalvo JJ, Rubén Zanchetta J, Insua AM.
    Endocr Pract; 2002 Dec; 8(2):96-101. PubMed ID: 11942772
    [Abstract] [Full Text] [Related]

  • 8. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
    Steinmetz A, Schwartz T, Hehnke U, Kaffarnik H.
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):563-70. PubMed ID: 8847874
    [Abstract] [Full Text] [Related]

  • 9. Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
    Hernández-Mijares A, Lluch I, Vizcarra E, Martínez-Triguero ML, Ascaso JF, Carmena R.
    Nutr Metab Cardiovasc Dis; 2000 Feb; 10(1):1-6. PubMed ID: 10812581
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E, De Gennes JL, Malbecq W, Baigts F.
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [Abstract] [Full Text] [Related]

  • 11. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA, Fanghänel-Salmón G, Meza E, Montes J, Gulías-Herrero A, Sánchez L, Monterrubio-Flores EA, González-Valdez H, Gómez Pérez FJ.
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [Abstract] [Full Text] [Related]

  • 12. Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose.
    Krysiak R, Handzlik G, Okopień B.
    Pharmacol Rep; 2010 Jun; 62(6):1099-107. PubMed ID: 21273667
    [Abstract] [Full Text] [Related]

  • 13. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
    Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H.
    Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
    [Abstract] [Full Text] [Related]

  • 14. [Levels of tumor necrosis factor alpha in serum of patients with hyperlipoproteinemia IIB before and after micronized fenofibrate therapy].
    Madej A, Okopień B, Kowalski J, Zieliński M, Wysocki J, Szyguła B, Kalina Z, Herman Z.
    Pol Arch Med Wewn; 1998 Apr; 99(4):308-13. PubMed ID: 9760818
    [Abstract] [Full Text] [Related]

  • 15. Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia.
    Okopien B, Huzarska M, Kulach A, Stachura-Kulach A, Madej A, Belowski D, Zielinski M, Herman ZS.
    J Cardiovasc Pharmacol; 2005 Feb; 45(2):160-4. PubMed ID: 15654265
    [Abstract] [Full Text] [Related]

  • 16. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.
    Liamis G, Kakafika A, Bairaktari E, Miltiadous G, Tsimihodimos V, Goudevenos J, Achimastos A, Elisaf M.
    Curr Med Res Opin; 2002 Feb; 18(3):125-8. PubMed ID: 12094821
    [Abstract] [Full Text] [Related]

  • 17. Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
    Sommariva D, Bonfiglioli D, Pogliaghi I, Ottomano C, Fasoli A.
    Eur J Clin Pharmacol; 1984 Feb; 26(6):741-4. PubMed ID: 6489413
    [Abstract] [Full Text] [Related]

  • 18. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
    Guerin M, Le Goff W, Frisdal E, Schneider S, Milosavljevic D, Bruckert E, Chapman MJ.
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
    [Abstract] [Full Text] [Related]

  • 19. Effect of ciprofibrate on C-reactive protein and fibrinogen levels.
    Rizos E, Kostoula A, Elisaf M, Mikhailidis DP.
    Angiology; 2002 Aug; 53(3):273-7. PubMed ID: 12025914
    [Abstract] [Full Text] [Related]

  • 20. The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia.
    Krysiak R, Gilowski W, Okopien B.
    Cardiovasc Ther; 2015 Oct; 33(5):270-4. PubMed ID: 26031507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.